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Summary Orofacial granulomatosis (OFG) is an uncommon disease, 
usually presenting as recurrent or persistent swelling of the soft tis-
sues in the orofacial region, predominantly lips (cheilitis granuloma-
tosa). The cause of this illness is unknown. OFG may also be part of the 
triad of Melkersson-Rosenthal syndrome (MRS) and some consider it a 
monosymptomatic form of MRS. We describe a case of a Croatian male 
patient with recurrent swelling limited to the upper lip for the past 
6 years. After establishing the diagnosis, we performed intralesional 
triamcinolone injections (16 mg, twice on a weekly schedule), result-
ing in complete remission. OFG differential diagnosis and treatment 
modalities are discussed.
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InTrODuCTIOn
The term orofacial granulomatosis (OFG) de-
scribes a nonspecific granulomatous inflammation 
of unknown origin, occurring on all parts of oral mu-
cosa, as well as on cheeks, chin and eyelids. Most of-
ten, it presents clinically as persistent or recurrent lip 
swelling, thus the term cheilitis granulomatosa (CG) 
was previously introduced by Miescher in 1945 (1). 
It is considered a monosymptomatic form of Melk-
ersson-Rosenthal syndrome (MRS), which, in its fully 
blown clinical picture, includes CG, facial nerve palsy, 
and fissured tongue (2,3). All three syndrome compo-
nents appear rarely, accounting up to only 8% to 25% 
of cases, the most common component being CG 
(4,5). Cheilitis granulomatosa usually appears in the 
second decade of life, more frequently in females (4). 
Two major diseases may be presented as CG: Crohn’s 
disease (6), and sarcoidosis (7,8). In terms of treat-
ment possibilities and outcome, OFG represents a 
very challenging and unpredictable condition.
CaSE rEpOrT
A male patient aged 48, with otherwise insignifi-
cant medical history, not taking any medications, had 
intermittent swelling of the upper lip and surrounding 
intraoral tissues for the past six years (Fig 1). Episodes 
recurred every 2-3 months and lasted several hours 
to several days. Palpatory finding included multiple 
indurated lip nodules. He also had fissured tongue. 
Angioedema was excluded (total serum IgE was nor-
mal, nutritional and environmental allergens were ex-
cluded by allergen-specific IgE antibody test). Panel 
tests for C1-esterase inhibitor levels and complement 
components C1 through C4 ruled out hereditary 
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angioedema. Dental origin was excluded by clinical 
examination, tooth vitality testing, and x-ray findings. 
No dental materials were present in the patient’s 
mouth. Medical history was insignificant for any gas-
trointestinal or digestive problems during the past 6 
years, giving not enough indications to suspect the 
possible Crohn’s disease. Sarcoidosis was excluded by 
the lack of respiratory symptoms, normal chest x-ray 
and normal serum angiotensin-converting enzyme 
(ACE) levels.
Upon exclusion of the above mentioned conditions, 
clinical features and palpatory findings of indurated lip 
nodules indicated idiopathic OFG. A finding of fissured 
tongue is consistent with oligosymptomatic Melkers-
son-Rosenthal syndrome without facial palsy.
Deep biopsy of the affected lip showed histologic 
features of perivascular and interstitial infiltrates of 
inflammatory cells composed of lymphocytes, plas-
ma cells and mast cells in subepithelial stroma (HE, 
200x; Giemsa, 400x) (Fig. 2). Histologic staining for 
acid fast bacteria was negative, thus excluding tuber-
culosis and deep mycoses. Polarizing foreign materi-
als were also excluded histologically. After fulfilling 
clinical and histopathologic criteria, the diagnosis of 
OFG was made.
After thorough application of topical xylocaine 
anesthetic spray, we performed intralesional treat-
ment with corticosteroid injections, according to 
Mignogna et al. (9). We injected 0.1 mL of triamcin-
olone acetonide (TA) (40 mg/mL) into each of the 4 
equidistant points on the border between upper lip 
vermillion and mucosa. In addition to TA, we added 
a small amount of epinephrine-free 3% mepivacaine 
local anesthetic to the injectable solution (0.05 mL 
of mepivacaine per injection point). The needle was 
inserted vertically towards the top. In order to avoid 
lip skin ischemia, the needle was directed slightly in-
wards. The total dose of TA was 16 mg per treatment. 
After one week, the procedure was repeated, result-
ing in full resolution (Fig. 3.), as assessed 7 days fol-
lowing 2nd treatment.
DISCuSSIOn
Orofacial granulomatosis is a recurrent disease, 
episodic, and intermittent, often recalcitrant to 
treatment. Complete and spontaneous remission is 
Figure 1. Swelling involving the entire upper lip.
Figure 2. Lip biopsy histologic finding revealing perivascu-
lar and interstitial infiltrates of inflammatory cells composed 
of lymphocytes, plasma cells and mast cells in subepithelial 
stroma (upper panel: HE, 200x; lower panel: Giemsa, 400x).
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unlikely. Some authors consider it the first clinical sign 
of MRS, or its mono-/oligo-symptomatic form (4,5,9), 
but there is no consensus on the subject. Apparently, 
up to 42% of MRS patients present with CG, whereas 
other signs may appear later in life. Others consider 
CG and MRS two different entities, as most of CG pa-
tients never develop MRS (10).
Histologically, it is characterized by noncaseating 
granulomatous inflammation (11,12). van der Waal et 
al. (10) state that, although noncaseating granulomas 
are classically present, the histology may be nonspe-
cific, with edema and perivascular lymphocytic in-
filtrate. There are 3 major groups of histopathology 
findings in OFG: 2 include noncaseating granulomas 
and one includes nonspecific inflammation (13). Thus, 
it can be concluded that biopsy without granulomas 
is not inconsistent with the diagnosis of CG. Dilated 
lymphatics in the superficial lamina propria and peri-
vascular aggregation of histiocytes and plasma cells 
usually are present, as in our case. Very deep muco-
sal biopsy should always be performed in order to 
increase the likelihood of finding granuloma. We ob-
tained a large specimen, roughly 10 mm deep and 10 
mm in diameter, but well organized granuloma was 
not present in that tissue sample. It is consistent with 
the findings of Perez-Calderon et al. (14), and a case 
presented by Bartell et al. (15), depicting “diffuse lym-
phocytic infiltrate in submucosa, with perivascular, 
poorly formed granulomas”. By thorough literature 
search, we could not find actual data on the percent-
age of noncaseating granulomas present in all OFG 
cases.
The diagnosis of CG is therefore a diagnosis of 
exclusion. It would include clinical, hematologic 
and histologic investigations in each patient, in ad-
dition to imaging techniques and radioallergosor-
bent and patch tests if dental materials are present. 
It is necessary to exclude the possible local (dental) 
and systemic diseases that can have similar clinical 
manifestations, including hypersensitivity reactions. 
Although IgE-mediated allergy was ruled out, our 
patient was regularly taking antihistamine fexofena-
dine 180 mg, without improvement in the swollen 
lip. It is a rather regular scenario, as OFG is generally 
not suspected. Further workup includes sarcoidosis, 
Crohn’s disease, tuberculosis, deep fungal infections, 
leprosy, leukemic infiltrate, and foreign body reac-
tions (6,8,11,16-18). Of those mentioned, two are of 
particular medical interest: sarcoidosis and Crohn’s 
disease. The former is unlikely in the absence of re-
spiratory problems, and if chest x-ray and ACE levels 
are normal. Biopsy of labial salivary gland can be of 
help in diagnosing sarcoidosis (18). Regarding the lat-
ter, the need for invasive evaluation in a patient with 
isolated granulomatous cheilitis is not recommend-
ed. This is pointed out in a review of 13 patients, in 
which the authors suggest that no specific diagnostic 
procedures should be undertaken if gastrointestinal 
complaints are absent (10).
The treatment of OFG is challenging, with fre-
quent recurrences despite different modalities ap-
plied. Medical management includes administration 
of nonsteroidal anti-inflammatory drugs, broad-spec-
trum antibiotics, antituberculous drugs, antileproma-
tous agents (clofazimine), sulfa drugs (sulfasalazine), 
antimalarials (hydroxycholoroquine), and steroids, 
be it systemic or intralesional (10,19-21). Surgically, 
cheiloplasty has shown some results, but would be 
suggested only for resistant cases, particularly when 
long-lasting chronic inflammation has caused fibrous 
tissue proliferation, when it is too late to use medica-
tions (22). Thus, early diagnosis and treatment is man-
datory for better outcome. Thalidomide has recently 
been shown to be effective in recalcitrant cases (23).
Among those mentioned above, corticoste-
roids are first-line treatment, as they are effective 
in swelling reduction (24,25). As the nature of OFG 
is relapsing, the use of systemic steroids has limita-
tions because of side effects. Thus, intralesional cor-
ticosteroid injections have been suggested (26). Re-
cently, delayed release concentrated TA (40 mg/mL) 
Figure 3. Complete resolution after 2 sessions of in-
tralesional corticosteroid treatment.
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has been pointed as the treatment of choice, used in 
small quantities of 0.1 mL (4 mg) per point of needle 
insertion (9). Previously, diluted concentration of TA 
(10 mg/mL) was advocated in OFG treatment, but a 
significantly higher volume of solution had to be in-
jected (amounting from 3 mL to up to 10 mL) (26). 
This approach has warranted previous application of 
local anesthetics, as the procedure would otherwise 
be painful due to the large amounts of the solution 
injected. Another problem was the dramatic increase 
of tissues after injections. We used a small amount of 
concentrated TA, and a cumulative dosage of 32 mg 
has proved sufficient for ongoing control of OFG for 
7 months to date, as compared to previous relapses 
occurring every 2-3 months. We did apply topical an-
esthesia prior to injecting triamcinolone. Adding a 
small amount of the epinephrine-free mepivacaine 
local anesthetic to triamcinolone solution (0.05 mL 
per injection point) significantly decreases discom-
fort during and after application, while only slightly 
increasing total volume.
Based on the previously published experience 
and the case presented, we suggest repeating the 
treatment on a weekly basis until complete response 
is achieved. This usually requires 2 to 3 applications 
(9). The potential side effects of corticosteroid such as 
temporary ischemia, hypopigmentation and soft tis-
sue atrophy may cause cosmetic problems. Thus, the 
needle insertion line should be inclined orally, and 
epinephrine-free anesthetic should be used, if any. 
The expected clinical response is appropriate but not 
permanent, most probably requiring repeated injec-
tions in the future (9,10,26).
COnCluSIOn
Differential diagnosis of swollen lips and swelling 
of other orofacial structures includes OFG. The diag-
nosis is made by excluding numerous other disease 
entities, e.g., Crohn’s disease and sarcoidosis, requir-
ing broad diagnostic workup. Orofacial granuloma-
tosis (or CG as one of its clinical forms) should be 
diagnosed early, as later in the course of the disease 
fibrous tissue may proliferate, thus narrowing treat-
ment options to surgery. Once OFG is diagnosed, 
successful and predictable treatment results may be 
achieved by repeated use of small doses of concen-
trated (40 mg/mL) slow release triamcinolone aceton-
ide intralesional injections, which should be regarded 
as first-line treatment.
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By rain and bad weather use Nivea cream; year 1935.
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